an SGLT-2 inhibitor, or a DPP-4 inhibitor between 2019 and 2024, NAION incidence ranged from 30 to 32 events per 100,000 person-years among GLP-1 RA users, 31 events per 100,000 person-years among SGLT-2 inhibitor users, and 26 events per 100,000 person-years among DPP-4 inhibitor users. Statistically, GLP-1 RAs did not show a significantly higher risk compared with SGLT-2 inhibitors, although there was a higher risk signal compared with DPP-4 inhibitors.
The FDA notes that other methodologically rigorous observational studies have also pointed toward an increased NAION risk